Skip to main content

  | मौसम…

411 समाचार
Public archive edition · Attributed source reporting with original dates · AI drafts are excluded

Repeal of ministerial control of RU486 bill passes Australian Senate

Licensed archive · Attributed source reporting

Wikinews contributors☆ सेव करें

411 Brief

The bill on whether the Australian Federal Health Minster Tony Abbott should not exercise ministerial control of the abortifacient RU486 has passed the Australian Senate February 9, 2006. If the bill passes the Australian House of Representatives, the Therapeutic Goods Administration (TGA) will exercise control and evaluation of the suitability of the drug for use in Australia. Senators were allowed a free vote on the issue. The result of the vote on the third reading, the final stage of the bill, was 45 for to 28 in favour of TGA exercising c

The bill on whether the Australian Federal Health Minster Tony Abbott should not exercise ministerial control of the abortifacient RU486 has passed the Australian Senate February 9, 2006. If the bill passes the Australian House of Representatives, the Therapeutic Goods Administration (TGA) will exercise control and evaluation of the suitability of the drug for use in Australia.

Senators were allowed a free vote on the issue. The result of the vote on the third reading, the final stage of the bill, was 45 for to 28 in favour of TGA exercising control. 23 of the 26 female senators voted in favour of the bill, while numbers were more evenly split between the male senators; 21 of them voted for the bill and 25 were against.

The bill will be debated in the House of Representatives on February 14, 2006.

Sources & reporting note

Licensed archive reporting by Wikinews contributors. Text: CC BY 2.5 (https://creativecommons.org/licenses/by/2.5/). Original source date retained. 411 has not independently verified this archive report.

Read the source: Wikinews ↗

Source published 9 Feb 2006, 05:30 am IST

इस खबर को पढ़ें:
Report an error

Reports and optional email addresses are visible only to the newsroom. Please avoid private or sensitive information.

आपके लिए और